Over the last few years, MEDICREA has had a role in revolutionizing the personalized spine surgery. Its ideas and patient-specific technologies have helped shape the future spine industry business model associating precise analysis of each patient and pre-op planning expert services to the implants. The company has been actively protecting these innovations through an aggressive patent strategy building a IP portfolio that includes 10 independent families, five issued patents and 16 pending applications.
The three newly allowed patents (U.S. Patent No 10,318,655; 10,314,657; 10,292,770) are directed to fundamental technologies and methods embedded in the UNiD ASI platform, a breakthrough in spine surgery. These additional allowances enable the company to further expand its existing patent portfolio as the firm continues to protect its technology directed to:
- The use of artificial intelligence and predictive modeling in spine surgery
- Systems and methods for generating data to produce patient-specific 2D and 3D rods
- Patient-specific screw planning and screw kit generation
- Patient-specific cage planning and production
- Intra operative monitoring device
MEDICREA’s proprietary UNiD ASI technology is a suite of services designed to help surgeons improve their patients' outcomes. By leveraging artificial intelligence and the latest clinical research, the platform enables the surgeon to plan cases preoperatively. The AI embedded within the platform allows a surgeon to visualize the compensatory mechanisms above and below the instrumented spine that will most likely occur based on the surgeon’s surgical plan. The surgeons work hand-in-hand with the UNiD Lab biomedical engineers who create several surgical plans and identify the one that would give the surgeon’s patient the best outcome.
Through rigorous and centralized processes, MEDICREA improves the content of its clinical database with each case, allowing the proprietary technology to continuously refine the algorithms behind its predictive model. With more than 4,000 cases performed through the UNiD ASI technology platform, all including patient-specific implants, this technology undoubtedly met a market need. The company plans to pursue its efforts to spread the technology and grow its clinical database.
Denys Sournac, CEO of MEDICREA, said, “MEDICREA is the pioneer in this new approach of spinal treatment and was able to file the very first patents covering these innovations. For this reason, the new patents issued create strong barriers to entry for competitors. It enables the company to maintain its competitive advantage and strengthen its position in the marketplace that is now obviously evolving into this direction. The company will pursue its permanent efforts of enhancing its very predictive model with the aim to always improve patient clinical outcomes”.
Through the lens of predictive medicine, MEDICREA leverages its proprietary software analysis tools with big data and machine learning technologies supported by an expansive collection of clinical and scientific data. The company operates in a $10 billion marketplace; it is a small and medium-sized enterprise (SME) with 200 employees worldwide, which includes 50 who are based in the United States. The company has an ultra-modern manufacturing facility in Lyon, France, housing the development and production of 3D- printed titanium patient-specific implants.